CD274 and cancer: Our group, however, recently published data in the November 2019 issue of Clinical Cancer Research that checkpoint blockade (anti-PD-L1) may also be particularly well-suited to functioning pituitary adenomas, such as those causing Cushing’s disease (CD) [2].